Exencial Wealth Advisors LLC Trims Stake in Humana Inc. (NYSE:HUM)

Exencial Wealth Advisors LLC lowered its stake in Humana Inc. (NYSE:HUMFree Report) by 48.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 630 shares of the insurance provider’s stock after selling 604 shares during the quarter. Exencial Wealth Advisors LLC’s holdings in Humana were worth $289,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Rakuten Securities Inc. purchased a new stake in Humana in the 4th quarter valued at approximately $25,000. Gradient Investments LLC lifted its stake in shares of Humana by 200.0% during the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 40 shares during the period. Cetera Trust Company N.A purchased a new position in shares of Humana during the 4th quarter worth $28,000. Private Wealth Management Group LLC purchased a new position in shares of Humana during the 4th quarter worth $32,000. Finally, Carolinas Wealth Consulting LLC lifted its stake in shares of Humana by 274.1% during the 4th quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock worth $46,000 after purchasing an additional 74 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on HUM shares. Argus lowered Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, March 13th. Barclays reduced their price target on Humana from $356.00 to $310.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 2nd. The Goldman Sachs Group cut their target price on Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a research report on Wednesday, April 3rd. Wells Fargo & Company cut their target price on Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a research report on Monday, April 8th. Finally, Raymond James initiated coverage on Humana in a research report on Friday, March 22nd. They issued a “market perform” rating on the stock. Thirteen investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, Humana presently has a consensus rating of “Hold” and an average price target of $423.63.

Read Our Latest Analysis on HUM

Humana Stock Down 1.0 %

Shares of Humana stock opened at $351.80 on Friday. The business has a 50-day moving average of $332.50 and a 200-day moving average of $361.86. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.67. The company has a market capitalization of $42.39 billion, a PE ratio of 21.91, a P/E/G ratio of 2.07 and a beta of 0.53. Humana Inc. has a 1-year low of $298.61 and a 1-year high of $530.54.

Humana (NYSE:HUMGet Free Report) last announced its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, beating the consensus estimate of $6.12 by $1.11. The company had revenue of $29.61 billion during the quarter, compared to the consensus estimate of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. The company’s revenue was up 10.7% on a year-over-year basis. During the same period last year, the firm earned $9.38 earnings per share. As a group, equities analysts forecast that Humana Inc. will post 16 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a dividend of $0.885 per share. The ex-dividend date is Friday, June 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.01%. Humana’s dividend payout ratio is presently 22.04%.

Humana Company Profile

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Further Reading

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.